VKTX - バイキング・セラピュ―ティクス (Viking Therapeutics Inc.) バイキング・セラピュ―ティクス

 VKTXのチャート


 VKTXの企業情報

symbol VKTx
会社名 Viking Therapeutics Inc (バイキング・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バイキング・セラピューティクス(Viking Therapeutics Inc.)は臨床段階バイオ医薬品会社である。同社は代謝及び内分泌障害治療法の開発に焦点を当てる。そのリード臨床プログラムVK5211は、第II相臨床試験下での経口投与可能な薬剤候補である。第二の臨床プログラムは、高コレステロール血症及び非アルコール性脂肪性肝炎(NASH)等副腎白質ジストロフィー(ALD)及び脂質障害のための甲状腺受容体ベータ(TRB)の分子アゴニストの開発に焦点を当てる。同社はまた、ALDの治療・潜在性予防のためのVK2809及びVK0214の開発に従事する。VK0612は、2型糖尿病ための経口投与可能な第IIb相対応薬剤候補である。同社の前臨床プログラムは、貧血治療用エリスロポエチン受容体(EPOR)アゴニストの同定、及び肥満症及び脂質異常症治療用ジアシルグリセロールアシルトランスフェラーゼ-1(DGAT-1)の組織・選択的阻害剤の開発に焦点を当てる。   バイキング・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。代謝及び内分泌疾患のための新規治療法の開発に焦点を当てる。主な臨床プログラムには、股関節骨折手術後のための非ステロイド系アンドロゲン受容体モジュレ―タ―の経口薬「VK5211」がある。また、副腎白質ジストロフィ―のための、小分子で経口投与可能な甲状腺受容体ベ―タを開発中。   Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
本社所在地 12340 El Camino Real Suite 250 San Diego CA 92130 USA
代表者氏名 Lawson Macartney ローソン・マッカートニー
代表者役職名 independent Chairman of the Board
電話番号 +1 858-704-4660
設立年月日 41153
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url www.vikingtherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/vktx
adr_tso
EBITDA EBITDA(百万ドル) -20.84878
終値(lastsale) 14.74
時価総額(marketcap) 894095883.56
時価総額 時価総額(百万ドル) 973.01920
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 830.85320
当期純利益 当期純利益(百万ドル) -20.40713
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Viking Therapeutics Inc revenues was not reported. Net loss decreased 2% to $10.2M. Lower net loss reflects Interest Expense/Income - Net increase from $3K (expense) to $573K (income) Change in fair value of debt conversion increase of 65% to $1.4M (income) Amortization of financing costs decrease of 88% to $60K (expense).

 VKTXのテクニカル分析


 VKTXのニュース

   Viking Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2022/01/09 06:27:14 Kwhen Finance
Viking Therapeutics Inc (VKTX) shares closed today at 0.5% above its 52 week low of $4.18, giving the company a market cap of $328M. The stock is currently down 8.7% year-to-date, down 33.6% over the past 12 months, and up 233.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 26.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 64.5% The company's stock price performance over the past 12 months lags the peer average by 67.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Viking Therapeutics (NASDAQ:VKTX) Shares Cross Below 50-Day Moving Average of $5.61  2021/12/24 08:18:41 ETF Daily News
Viking Therapeutics, Inc. (NASDAQ:VKTX)s share price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $5.61 and traded as low as $4.86. Viking Therapeutics shares last traded at $5.18, with a volume of 841,181 shares. A number of equities analysts have commented on [] The post Viking Therapeutics (NASDAQ:VKTX) Shares Cross Below 50-Day Moving Average of $5.61 appeared first on ETF Daily News .
   Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $13.93  2021/12/23 23:34:43 Transcript Daily
Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) have been given a consensus rating of Buy by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a report on the stock in []
   Viking Therapeutics Inc. (NASDAQ: VKTX): Whats Next In 2021?  2021/12/18 13:00:00 Stocks Register
Viking Therapeutics Inc. (NASDAQ:VKTX) shares, rose in value on Friday, 12/17/21, with the stock price up by 5.59% to the previous days close as strong demand from buyers drove the stock to $4.91. Actively observing the price movement in the last trading, the stock closed the session at $4.65, falling within a range of $4.60 Viking Therapeutics Inc. (NASDAQ: VKTX): Whats Next In 2021? Read More »
   Metropolitan Life Insurance Co NY Increases Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)  2021/12/06 09:46:41 Dakota Financial News
Metropolitan Life Insurance Co NY grew its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 47,695.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,559 shares of the biotechnology companys stock after buying an additional 9,539 shares during the quarter. Metropolitan Life []
   Viking Therapeutics, Inc. (NASDAQ:VKTX) Expected to Post Earnings of -$0.19 Per Share  2021/11/20 15:36:41 Transcript Daily
Equities research analysts forecast that Viking Therapeutics, Inc. (NASDAQ:VKTX) will post ($0.19) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Viking Therapeutics earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.22). Viking Therapeutics reported earnings of ($0.15) per share in the []
   Viking Therapeutics (NASDAQ:VKTX) Now Covered by Analysts at Maxim Group  2021/11/13 17:42:41 Transcript Daily
Maxim Group initiated coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note published on Friday morning, TipRanks reports. The firm issued a buy rating and a $14.00 target price on the biotechnology companys stock. Several other research firms also recently commented on VKTX. Zacks Investment Research upgraded shares of Viking Therapeutics from a []
   Viking Therapeutics (NASDAQ:VKTX) Coverage Initiated by Analysts at Maxim Group  2021/11/13 17:04:41 Dakota Financial News
Maxim Group initiated coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note issued on Friday, TipRanks reports. The firm set a buy rating and a $14.00 price target on the biotechnology companys stock. Maxim Groups price objective indicates a potential upside of 127.64% from the companys current price. VKTX has been the topic []
   Geode Capital Management LLC Purchases 95,701 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)  2021/11/11 09:30:41 Dakota Financial News
Geode Capital Management LLC raised its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 9.0% during the 2nd quarter, Holdings Channel.com reports. The fund owned 1,160,325 shares of the biotechnology companys stock after acquiring an additional 95,701 shares during the period. Geode Capital Management LLCs holdings in Viking Therapeutics were worth $6,950,000 as of []
   Viking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from BMO Capital Markets  2021/11/11 08:46:43 Transcript Daily
BMO Capital Markets reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report released on Monday morning, Price Targets.com reports. They currently have a $15.00 price target on the biotechnology companys stock. Other equities research analysts also recently issued reports about the stock. Raymond James lifted their price target on shares []
   Viking Therapeutics to Participate in Upcoming Investor Conferences  2021/09/02 20:05:00 PR Newswire
SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming
   Viking Therapeutics: Remaining Bullish And Sticking To My Plan  2021/08/27 15:52:04 Seeking Alpha
   Viking Therapeutics (VKTX) Investor Presentation - Slideshow  2021/08/13 19:36:01 Seeking Alpha
   Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2021 Results - Earnings Call Transcript  2021/07/29 01:27:09 Seeking Alpha
   Viking Therapeutics shares fall after wider Q2 net loss  2021/07/28 21:00:06 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バイキング・セラピュ―ティクス VKTX Viking Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)